Ipca LaboratoriesNSE:IPCALAB -0.18%86 EBITDA Margin % is 22.26% as of Mar. 2026, which is 16% above its 10-year median of 19.15. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,594.77 (Fairly Valued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Ipca Laboratories ranks better than 71.41% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ipca Laboratories's EBITDA for the
three
months ended in Mar. 2026 was ₹5,318 Mil. Ipca Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹23,885 Mil. Therefore, Ipca Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 22.26%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ipca Laboratories EBITDA Margin % Related Terms
Ipca Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories (NSE:IPCALAB) has a EBITDA Margin % of 22.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ipca Laboratories and its competitors. This is 16% above median its historical median of 19.15. Over the past decade, Ipca Laboratories' EBITDA Margin % has ranged from 14.74 to 29.94. According to the industry distribution chart, Ipca Laboratories ranks #273 out of 955 companies in the Drug Manufacturers industry, placing it in the top 28.6%.
Is Ipca Laboratories' EBITDA Margin % too high?
Ipca Laboratories' current EBITDA Margin % of 22.26% is 16% above median its 10-year median of 19.15. Over the past 10 years, this metric has ranged from a low of 14.74 to a high of 29.94. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Ipca Laboratories' value of 22.26% is 78.9% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #273 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #273 out of 955 companies for EBITDA Margin %. This puts Ipca Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Ipca Laboratories' value of 22.26% is 78.9% above this benchmark. Historically, Ipca Laboratories' own EBITDA Margin % has ranged from 14.74 to 29.94 over the past decade. While the company's 10-year median is 19.15 vs. the industry median of 12.44, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current EBITDA Margin % of 22.26% is 78.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current EBITDA Margin % is 22.26%, which is 16% above median its own 10-year median of 19.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,594.77, compared to a current price of ₹1,618.30 — trading 1.5% above its estimated fair value. The current EBITDA Margin % is 22.26%, which is 16% above median its 10-year median of 19.15 and 78.9% above the Drug Manufacturers industry median of 12.44. Ipca Laboratories' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current EBITDA Margin % is 22.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,618.30 is trading 1.5% above its estimated GF Value™ of ₹1,594.77.
GuruFocus considers Ipca Laboratories to be Fairly Valued.
Key valuation signals for NSE:IPCALAB:
EBITDA Margin %: 22.26% (16% above median its 10-year median of 19.15)
GF Value™: ₹1,594.77 vs. price of ₹1,618.30 (1.5% above fair value)
Industry Position: 78.9% above the Drug Manufacturers median (#273 of 955)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score
Get the complete analysis for NSE:IPCALAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
